Chase Knickerbocker
Stock Analyst at Craig-Hallum
(4.35)
# 344
Out of 4,944 analysts
44
Total ratings
54.76%
Success rate
19.07%
Average return
Main Sectors:
Stocks Rated by Chase Knickerbocker
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| DMAC DiaMedica Therapeutics | Maintains: Buy | $8 → $11 | $5.22 | +110.73% | 1 | Jul 18, 2025 | |
| BFLY Butterfly Network | Initiates: Buy | $3 | $1.39 | +115.83% | 1 | Jul 1, 2025 | |
| INDV Indivior | Maintains: Buy | $15 → $22 | $22.84 | -3.68% | 4 | Jun 30, 2025 | |
| NRXS NeurAxis | Initiates: Buy | $7 | $2.49 | +181.12% | 1 | Jun 16, 2025 | |
| PHAT Phathom Pharmaceuticals | Maintains: Buy | $12 → $17 | $10.38 | +63.78% | 3 | Jun 9, 2025 | |
| FENC Fennec Pharmaceuticals | Maintains: Buy | $12 → $13 | $9.24 | +40.69% | 5 | May 14, 2025 | |
| ETON Eton Pharmaceuticals | Maintains: Buy | $26 → $28 | $17.32 | +61.66% | 6 | May 14, 2025 | |
| XERS Xeris Biopharma Holdings | Maintains: Buy | $5 → $6.5 | $7.30 | -10.96% | 1 | Mar 7, 2025 | |
| MDWD MediWound | Initiates: Buy | $39 | $18.82 | +107.23% | 1 | Feb 28, 2025 | |
| IRWD Ironwood Pharmaceuticals | Maintains: Buy | $10 → $8 | $0.98 | +714.25% | 4 | Jan 22, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $18 → $21 | $10.88 | +93.01% | 2 | Jan 17, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $5 → $6 | $4.15 | +44.58% | 2 | Jan 17, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $16 → $12 | $4.80 | +150.00% | 2 | Nov 14, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $10 | $3.42 | +192.40% | 1 | Nov 4, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $45 → $65 | $34.83 | +86.62% | 3 | Oct 4, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $14 → $12 | $7.23 | +65.98% | 2 | Aug 1, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $10 | $8.07 | +23.92% | 1 | Jul 11, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $22 → $23 | $13.40 | +71.64% | 2 | May 9, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $1 → $1.2 | $0.67 | +79.10% | 2 | Jul 11, 2023 |
DiaMedica Therapeutics
Jul 18, 2025
Maintains: Buy
Price Target: $8 → $11
Current: $5.22
Upside: +110.73%
Butterfly Network
Jul 1, 2025
Initiates: Buy
Price Target: $3
Current: $1.39
Upside: +115.83%
Indivior
Jun 30, 2025
Maintains: Buy
Price Target: $15 → $22
Current: $22.84
Upside: -3.68%
NeurAxis
Jun 16, 2025
Initiates: Buy
Price Target: $7
Current: $2.49
Upside: +181.12%
Phathom Pharmaceuticals
Jun 9, 2025
Maintains: Buy
Price Target: $12 → $17
Current: $10.38
Upside: +63.78%
Fennec Pharmaceuticals
May 14, 2025
Maintains: Buy
Price Target: $12 → $13
Current: $9.24
Upside: +40.69%
Eton Pharmaceuticals
May 14, 2025
Maintains: Buy
Price Target: $26 → $28
Current: $17.32
Upside: +61.66%
Xeris Biopharma Holdings
Mar 7, 2025
Maintains: Buy
Price Target: $5 → $6.5
Current: $7.30
Upside: -10.96%
MediWound
Feb 28, 2025
Initiates: Buy
Price Target: $39
Current: $18.82
Upside: +107.23%
Ironwood Pharmaceuticals
Jan 22, 2025
Maintains: Buy
Price Target: $10 → $8
Current: $0.98
Upside: +714.25%
Jan 17, 2025
Maintains: Buy
Price Target: $18 → $21
Current: $10.88
Upside: +93.01%
Jan 17, 2025
Maintains: Buy
Price Target: $5 → $6
Current: $4.15
Upside: +44.58%
Nov 14, 2024
Maintains: Buy
Price Target: $16 → $12
Current: $4.80
Upside: +150.00%
Nov 4, 2024
Initiates: Buy
Price Target: $10
Current: $3.42
Upside: +192.40%
Oct 4, 2024
Maintains: Buy
Price Target: $45 → $65
Current: $34.83
Upside: +86.62%
Aug 1, 2024
Maintains: Buy
Price Target: $14 → $12
Current: $7.23
Upside: +65.98%
Jul 11, 2024
Initiates: Buy
Price Target: $10
Current: $8.07
Upside: +23.92%
May 9, 2024
Maintains: Buy
Price Target: $22 → $23
Current: $13.40
Upside: +71.64%
Jul 11, 2023
Maintains: Buy
Price Target: $1 → $1.2
Current: $0.67
Upside: +79.10%